SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Mar. 3, 2026-- Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company pioneering neuroscience with nose-to-brain neurocircuitry to develop and commercialize a new class of intranasal product candidates called pherines, today announced

SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Feb. 25, 2026-- Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company pioneering neuroscience with nose-to-brain neurocircuitry to develop and commercialize a new class of intranasal product candidates called pherines, will present

PALISADE-4 Phase 3 Trial of fasedienol for acute treatment of Social Anxiety Disorder proceeding, with topline results from the randomized portion of the trial expected in the first half of 2026 SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Feb. 12, 2026-- Vistagen (Nasdaq: VTGN), a late

SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Feb. 4, 2026-- Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company pioneering neuroscience with nose-to-brain neurocircuitry to develop and commercialize a new class of intranasal product candidates called pherines, today announced

Study did not demonstrate statistically significant improvement on primary endpoint of reduction in anxiety as measured by SUDS scores compared to placebo Favorable safety and tolerability data were consistent with previous studies Company’s cash preservation measures expected to provide runway

SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Dec. 1, 2025-- Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company pioneering neuroscience with nose-to-brain neurocircuitry to develop and commercialize a new class of intranasal product candidates called pherines, today announced

Research supports the product candidate’s non-hormonal, non-systemic, rapidly-acting effects on autonomic biomarkers SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Nov. 26, 2025-- Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company pioneering neuroscience with nose-to-brain

PALISADE-3 Phase 3 Public Speaking Challenge Study of Fasedienol for the Acute Treatment of Social Anxiety Disorder is Complete; Topline results expected by calendar year end SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Nov. 13, 2025-- Vistagen (Nasdaq: VTGN), a late clinical-stage

SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Nov. 10, 2025-- Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company pioneering neuroscience with nose-to-brain neurocircuitry to develop and commercialize a new class of intranasal product candidates called pherines, today

SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Nov. 5, 2025-- Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company pioneering neuroscience with nose-to-brain neurocircuitry to develop and commercialize a new class of intranasal product candidates called pherines, today announced